Loading...
Loading...
Contributors:
Dataset URI:
10.1021/acs.jmedchem.5c01176.s002The apelinergic system comprises the peptidergic GPCR apelin receptor (APLNR) and two distinct classes of endogenous peptides called apelin and ELA/Apela. Regulation of the apelinergic system is a promising therapeutic approach for insulin resistance associated with metabolic syndrome. While small-molecule agonists of the apelin receptor have been described previously, well-characterized central nervous system (CNS)-penetrant compounds are needed. Herein, we describe the discovery and characterization of a novel set of pyrazole- and imidazole-based APLNR agonists. Of these, the imidazole 35 was identified as a potent, CNS-penetrant biased agonist of APLNR with significant bias (∼8-fold) for G-protein over β-arrestin 2 signaling. This compound is orally active with good pharmacokinetic properties. Treatment of obese diabetic mice with 35 improved insulin resistance.
Keyword(s):
35; apelin receptor; apelinergic system; apelinergic system comprises; arrestin 2 signaling.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)